Exelixis
EXEL
#1833
Rank
HK$85.48 B
Marketcap
HK$318.84
Share price
-1.06%
Change (1 day)
10.32%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): HK$18.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$18.63. In 2023 the company made an earnings per share (EPS) of HK$5.11 an increase over its 2022 EPS that were of HK$4.46.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$18.56
2023HK$5.1114.61%
2022HK$4.46-22.97%
2021HK$5.79100%
2020HK$2.90-65.09%
2019HK$8.30-53.91%
2018HK$18.00333.96%
2017HK$4.15-260.61%
2016-HK$2.58-58.75%
2015-HK$6.26-42.45%
2014-HK$10.885.3%
2013-HK$10.33

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$87.17 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$10.64-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$112.16 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$16.16-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$57.19 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$23.25 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$29.49 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$28.73-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.57-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA